tetano
Editor, Senior Moderator
Health Sci Rep
. 2022 Jun 16;5(4):e700.
doi: 10.1002/hsr2.700. eCollection 2022 Jul.
Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review
Neha Mehta[SUP] 1 [/SUP], Sangam Shah[SUP] 2 3 [/SUP], Kiran Paudel[SUP] 4 [/SUP], Rajan Chamlagain[SUP] 1 [/SUP], Santosh Chhetri[SUP] 5 [/SUP]
Affiliations
Abstract
Background and aims: Patients on maintenance dialysis are a high-risk, immune-compromised population with 15%-25% coronavirus disease (COVID-19) mortality rate that has been underrepresented in COVID-19 vaccination clinical trials. The aim of study was to review of those studies to determine the safety and efficacy of the COVID-19 vaccination in chronic kidney disease (CKD) patients receiving maintenance hemodialysis systematically.
Methods: The effectiveness was assessed by looking at the humoral and cellular responses. The humoral response is defined as de novo IgG- or IgA-anti-SpikeS1 antibody positivity. The establishment of de novo T-cell immunity after immunization was used to measure cellular response. Adverse results were also reported of the included studies to analyze the safety of COVID-19 vaccines. Eight previous works were included in our study.
Results: Two doses of COVID-19 vaccines were shown to be effective with seroconversion rate of humoral response ranging from 81% to 97% among eight studies. The T-cell response was shown 67% and 100% in two studies. COVID-19 vaccines did not have notable adverse events and hence can be considered safe.
Conclusion: Although a single dosage has not shown to improve humoral immune response in most hemodialysis trials, a double dose has been reported to improve seroconversion rate and humoral immune response. Further research are required to observe if hemodialysis patients generate effective T-cell responses.
Keywords: CKD; COVID‐19; Moderna; Pfizer; hemodialysis; vaccine.
. 2022 Jun 16;5(4):e700.
doi: 10.1002/hsr2.700. eCollection 2022 Jul.
Safety and efficacy of coronavirus disease-19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review
Neha Mehta[SUP] 1 [/SUP], Sangam Shah[SUP] 2 3 [/SUP], Kiran Paudel[SUP] 4 [/SUP], Rajan Chamlagain[SUP] 1 [/SUP], Santosh Chhetri[SUP] 5 [/SUP]
Affiliations
- PMID: 35755410
- PMCID: PMC9203992
- DOI: 10.1002/hsr2.700
Abstract
Background and aims: Patients on maintenance dialysis are a high-risk, immune-compromised population with 15%-25% coronavirus disease (COVID-19) mortality rate that has been underrepresented in COVID-19 vaccination clinical trials. The aim of study was to review of those studies to determine the safety and efficacy of the COVID-19 vaccination in chronic kidney disease (CKD) patients receiving maintenance hemodialysis systematically.
Methods: The effectiveness was assessed by looking at the humoral and cellular responses. The humoral response is defined as de novo IgG- or IgA-anti-SpikeS1 antibody positivity. The establishment of de novo T-cell immunity after immunization was used to measure cellular response. Adverse results were also reported of the included studies to analyze the safety of COVID-19 vaccines. Eight previous works were included in our study.
Results: Two doses of COVID-19 vaccines were shown to be effective with seroconversion rate of humoral response ranging from 81% to 97% among eight studies. The T-cell response was shown 67% and 100% in two studies. COVID-19 vaccines did not have notable adverse events and hence can be considered safe.
Conclusion: Although a single dosage has not shown to improve humoral immune response in most hemodialysis trials, a double dose has been reported to improve seroconversion rate and humoral immune response. Further research are required to observe if hemodialysis patients generate effective T-cell responses.
Keywords: CKD; COVID‐19; Moderna; Pfizer; hemodialysis; vaccine.